The genome editor CRISPR, whose invention is at the heart of a fierce patent battle, typically uses a RNA molecule (red) to guide a DNA-cutting enzyme such as Cas9 (orange) to a DNA sequence (blue) targeted for cutting.
By Jon CohenThe long-running patent battle over CRISPR, the genome editor that may bring a Nobel prize and many millions of dollars to whomever is credited with its invention, has taken a new twist that vastly complicates the claims made by a team led by the University of California.The Patent Trial and Appeal Board (PTAB) ruled 10 September that a group led by the Broad Institute has “priority” in its already granted patents for uses of the original CRISPR system in eukaryotic cells, which covers potentially lucrative.
Read more on sciencemag.org